{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:07:24Z","timestamp":1757624844067,"version":"3.44.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The location of nasopharyngeal carcinoma (NPC) is relatively hidden. Most patients are diagnosed at the middle or late stage of the disease, having missed the best time for treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To explore the clinical value of lncRNA FAM3D-AS1 and its effect on tumor progression and cisplatin resistance in nasopharyngeal cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>In this study, a total of 118 NPC patients and 50 healthy volunteers participated. RT-qPCR was analyzed to detect the lncRNA FAM3D-AS1 expression in NPC patients and cells. Receiver Operating Characteristic (ROC curves), Kaplan-Meier (K-M) survival curves and Cox regression analysis were performed to analyze the clinical value value of lncRNA FAM3D-AS1. Cell functional assays were employed to investigate the impact of lncRNA FAM3D-AS1 on biological malignant behavior of NPC and cisplatin resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In NPC patients\u2019 serum and cell lines, the expression of lncRNA FAM3D-AS1 was upregulated. ROC curves with Area Under the Curve (AUC)\u2009=\u20090.920, 95%CI\u2009=\u20090.874\u20130.965 could be used to distinguish the healthy group from the NPC group. K-M survival curves revealed that NPC patients with high expression of lncRNA FAM3D-AS1 had poor prognosis. Cox regression analysis suggested that lncRNA FAM3D-AS1 was an independent prognostic marker for NPC. Knockdown of lncRNA FAM3D-AS1 expression prohibited NPC cell proliferation, migration, invasion, and cisplatin resistance, but promoted apoptosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>LncRNA FAM3D-AS1 can be used as a biomarker to diagnose and prognosticate NPC. LncRNA FAM3D-AS1 affects tumor progression and cisplatin resistance in NPC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00526-0","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T10:20:38Z","timestamp":1756203638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The diagnostic and prognostic value of LncRNA FAM3D-AS1 expression in nasopharyngeal carcinoma and its effect on tumor progression and cisplatin resistance"],"prefix":"10.1186","volume":"162","author":[{"given":"Bohan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhinong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"10192","key":"526_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London England). 2019;394(10192):64\u201380.","journal-title":"Lancet (London England)"},{"key":"526_CR2","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.ctrv.2019.101890","volume":"79","author":"AWM Lee","year":"2019","unstructured":"Lee AWM, Ng WT, Chan JYW, Corry J, M\u00e4kitie A, Mendenhall WM, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890.","journal-title":"Cancer Treat Rev"},{"key":"526_CR3","doi-asserted-by":"publisher","first-page":"1079515","DOI":"10.3389\/fimmu.2022.1079515","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Duan X, Chen X, Zhan M, Peng H, Meng Y, et al. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front Immunol. 2022;13:1079515.","journal-title":"Front Immunol"},{"issue":"8","key":"526_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41418-022-00939-8","volume":"29","author":"L Yuan","year":"2022","unstructured":"Yuan L, Li S, Chen Q, Xia T, Luo D, Li L, et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 2022;29(8):1513\u201327.","journal-title":"Cell Death Differ"},{"issue":"1","key":"526_CR5","doi-asserted-by":"publisher","first-page":"20230673","DOI":"10.1515\/med-2023-0673","volume":"18","author":"J Yang","year":"2023","unstructured":"Yang J, Yang L, Han Q, Zhang Y, Tao Z, Zhou Y, et al. The dose limits of teeth protection for patients with nasopharyngeal carcinoma undergoing radiotherapy based on the early oral health-related quality of life. Open Med (Warsaw Poland). 2023;18(1):20230673.","journal-title":"Open Med (Warsaw Poland)"},{"issue":"3","key":"526_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10555-024-10176-9","volume":"43","author":"ZY Su","year":"2024","unstructured":"Su ZY, Siak PY, Lwin YY, Cheah SC. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024;43(3):919\u201339.","journal-title":"Cancer Metastasis Rev"},{"issue":"Pt 4","key":"526_CR7","doi-asserted-by":"publisher","first-page":"137809","DOI":"10.1016\/j.ijbiomac.2024.137809","volume":"283","author":"K Wang","year":"2024","unstructured":"Wang K, Zhu L, Gong H, Huang K, Luo H, Yu W, et al. ANXA6 expression as a potential indicator of tumor diagnosis, metastasis and immunity in nasopharyngeal carcinoma. Int J Biol Macromol. 2024;283(Pt 4):137809.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"526_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/br.2024.1831","volume":"21","author":"YT Wu","year":"2024","unstructured":"Wu YT, Lin CH, Chiu WC, Hsieh TJ, Chang SJ, Chang YC, et al. Treatment with autophagic inhibitors enhances oligonol\u2013induced apoptotic effects in nasopharyngeal carcinoma cells. Biomedical Rep. 2024;21(4):143.","journal-title":"Biomedical Rep"},{"key":"526_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","volume":"19","author":"ZL Huang","year":"2019","unstructured":"Huang ZL, Liu S, Wang GN, Zheng SH, Ding SR, Tao YL, et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int. 2019;19:141.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"526_CR10","first-page":"55","volume":"38","author":"PY OuYang","year":"2018","unstructured":"OuYang PY, You KY, Zhang LN, Xiao Y, Zhang XM, Xie FY. External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC\/UICC staging system: a retrospective cohort study. Cancer Commun (London England). 2018;38(1):55.","journal-title":"Cancer Commun (London England)"},{"key":"526_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.yexmp.2019.04.003","volume":"108","author":"TJ Shin","year":"2019","unstructured":"Shin TJ, Lee KH, Cho HM, Cho JY. Concise approach for screening long non-coding RNAs functionally linked to human breast cancer associated genes. Exp Mol Pathol. 2019;108:89\u201396.","journal-title":"Exp Mol Pathol"},{"key":"526_CR12","doi-asserted-by":"publisher","first-page":"1327281","DOI":"10.3389\/fimmu.2024.1327281","volume":"15","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Lu G, Li N, Hu Y, Tan H, Jiang C. Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment. Front Immunol. 2024;15:1327281.","journal-title":"Front Immunol"},{"key":"526_CR13","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.2147\/OTT.S205169","volume":"12","author":"B Zhao","year":"2019","unstructured":"Zhao B, Lu Y, Cao X, Zhu W, Kong L, Ji H, et al. MiRNA-124 inhibits the proliferation, migration and invasion of cancer cell in hepatocellular carcinoma by downregulating lncRNA-UCA1. OncoTargets Therapy. 2019;12:4509\u201316.","journal-title":"OncoTargets Therapy"},{"key":"526_CR14","doi-asserted-by":"publisher","first-page":"845418","DOI":"10.3389\/fimmu.2022.845418","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Shen J, Wu Y, Ruan W, Zhu F, Duan S. LINC00520: A potential diagnostic and prognostic biomarker in cancer. Front Immunol. 2022;13:845418.","journal-title":"Front Immunol"},{"issue":"4","key":"526_CR15","doi-asserted-by":"publisher","first-page":"11026","DOI":"10.1080\/21655979.2022.2067292","volume":"13","author":"N He","year":"2022","unstructured":"He N, Xiang L, Chen L, Tong H, Wang K, Zhao J, et al. The role of long non-coding RNA FGD5-AS1 in cancer. Bioengineered. 2022;13(4):11026\u201341.","journal-title":"Bioengineered"},{"key":"526_CR16","doi-asserted-by":"crossref","unstructured":"Chen KL, Huang SW, Yao JJ, He SW, Gong S, Tan XR et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2024;76:101111.","DOI":"10.1016\/j.drup.2024.101111"},{"issue":"9","key":"526_CR17","doi-asserted-by":"publisher","first-page":"e1361","DOI":"10.1002\/ctm2.1361","volume":"13","author":"X Hu","year":"2023","unstructured":"Hu X, Wu J, Feng Y, Ma H, Zhang E, Zhang C, et al. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma. Clin Translational Med. 2023;13(9):e1361.","journal-title":"Clin Translational Med"},{"key":"526_CR18","first-page":"101034","volume-title":"LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44","author":"J Mi","year":"2024","unstructured":"Mi J, Wang Y, He S, Qin X, Li Z, Zhang T, et al. LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44. Volume 56. New York, NY: Neoplasia; 2024. p. 101034."},{"key":"526_CR19","doi-asserted-by":"publisher","first-page":"103522","DOI":"10.1016\/j.ebiom.2021.103522","volume":"70","author":"L Zhong","year":"2021","unstructured":"Zhong L, Dong D, Fang X, Zhang F, Zhang N, Zhang L, et al. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre study. EBioMedicine. 2021;70:103522.","journal-title":"EBioMedicine"},{"issue":"9","key":"526_CR20","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1001\/jamaoncol.2024.2519","volume":"10","author":"P Bayatfard","year":"2024","unstructured":"Bayatfard P, Sari SY, Yazici G, Chemotherapy. Radiation therapy, and nasopharyngeal carcinoma. JAMA Oncol. 2024;10(9):1292.","journal-title":"JAMA Oncol"},{"key":"526_CR21","doi-asserted-by":"publisher","first-page":"844778","DOI":"10.3389\/fimmu.2022.844778","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang N, Wu J, Gao X, Zhao H, Liu Z, et al. 5-Methylcytosine related LncRNAs reveal immune characteristics, predict prognosis and oncology treatment outcome in Lower-Grade gliomas. Front Immunol. 2022;13:844778.","journal-title":"Front Immunol"},{"issue":"2","key":"526_CR22","doi-asserted-by":"publisher","first-page":"188502","DOI":"10.1016\/j.bbcan.2021.188502","volume":"1875","author":"B Goyal","year":"2021","unstructured":"Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB, Gupta SC. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Et Biophys Acta Reviews Cancer. 2021;1875(2):188502.","journal-title":"Biochim Et Biophys Acta Reviews Cancer"},{"issue":"Pt B","key":"526_CR23","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ijbiomac.2022.09.209","volume":"222","author":"AE Fattah","year":"2022","unstructured":"Fattah AE, Abulsoud YK, AbdelHamid AI, Hamdy SG. Interactome battling of LncRNA CCDC144NL-AS1: its role in the emergence and ferocity of cancer and beyond. Int J Biol Macromol. 2022;222(Pt B):1676\u201387.","journal-title":"Int J Biol Macromol"},{"key":"526_CR24","doi-asserted-by":"crossref","unstructured":"Wu D, Zhou Y, Fan Y, Zhang Q, Gu F, Mao W et al. LncRNA CAIF was downregulated in end-stage cardiomyopathy and is a promising diagnostic and prognostic marker for this disease. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2019;24(8):735\u20138.","DOI":"10.1080\/1354750X.2019.1677778"},{"issue":"7","key":"526_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2018-0929","volume":"57","author":"W Zong","year":"2019","unstructured":"Zong W, Feng W, Jiang Y, Ju S, Cui M, Jing R. Evaluating the diagnostic and prognostic value of serum long non-coding RNA CTC-497E21.4 in gastric cancer. Clin Chem Lab Med. 2019;57(7):1063\u201372.","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"526_CR26","first-page":"246","volume":"37","author":"D Mao","year":"2022","unstructured":"Mao D, Jie Y, Lv Y. LncRNA SNHG6 induces Epithelial-Mesenchymal transition of pituitary adenoma via suppressing MiR-944. Cancer Biother Radiopharm. 2022;37(4):246\u201355.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"526_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s11658-023-00471-8","volume":"28","author":"X Shen","year":"2023","unstructured":"Shen X, Jin X, Fang S, Chen J. EFEMP2 upregulates PD-L1 expression via EGFR\/ERK1\/2\/c-Jun signaling to promote the invasion of ovarian cancer cells. Cell Mol Biol Lett. 2023;28(1):53.","journal-title":"Cell Mol Biol Lett"},{"key":"526_CR28","doi-asserted-by":"publisher","first-page":"100297","DOI":"10.1016\/j.aohep.2020.100297","volume":"23","author":"J Yao","year":"2021","unstructured":"Yao J, Fu J, Liu Y, Qu W, Wang G, Yan Z. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. Ann Hepatol. 2021;23:100297.","journal-title":"Ann Hepatol"},{"issue":"4","key":"526_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3724\/abbs.2023010","volume":"55","author":"F Wu","year":"2023","unstructured":"Wu F, Zhang W, Wei H, Ma H, Leng G, Zhang Y. LncRNA ELFN1-AS1 promotes proliferation, migration and invasion and suppresses apoptosis in colorectal cancer cells by enhancing G6PD activity. Acta Biochim Biophys Sin. 2023;55(4):649\u201360.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"526_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12885-022-09426-2","volume":"22","author":"J Bie\u0144kiewicz","year":"2022","unstructured":"Bie\u0144kiewicz J, Romanowicz H, Szyma\u0144ska B, Doma\u0144ska-Senderowska D, Wilczy\u0144ski M, Stepowicz A, et al. Analysis of LncRNA sequences: FAM3D-AS1, LINC01230, LINC01315 and LINC01468 in endometrial cancer. BMC Cancer. 2022;22(1):343.","journal-title":"BMC Cancer"},{"issue":"2","key":"526_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41419-021-03417-0","volume":"12","author":"C Cheng","year":"2021","unstructured":"Cheng C, Yang J, Li SW, Huang G, Li C, Min WP, et al. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target. Cell Death Dis. 2021;12(2):137.","journal-title":"Cell Death Dis"},{"issue":"1","key":"526_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-022-02282-9","volume":"41","author":"B He","year":"2022","unstructured":"He B, Pan H, Zheng F, Chen S, Bie Q, Cao J, et al. Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor Glycolysis and cell proliferation in nasopharyngeal carcinoma. J Experimental Clin Cancer Research: CR. 2022;41(1):77.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"7","key":"526_CR33","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.21873\/anticanres.15837","volume":"42","author":"P Prathaphan","year":"2022","unstructured":"Prathaphan P, Reamtong O, Ngaokrajang U, Janvilisri T, Swainson NM, Kiatwuthinon P. Comparative proteomic profiling of Cisplatin-resistant nasopharyngeal carcinoma cell lines: novel biomarkers for improving chemotherapy of NPC. Anticancer Res. 2022;42(7):3507\u201322.","journal-title":"Anticancer Res"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00526-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:16:43Z","timestamp":1757434603000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00526-0","relation":{},"ISSN":["1601-5223"],"issn-type":[{"type":"electronic","value":"1601-5223"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Xianning Central Hospital before the study began. The written informed consent has been obtained from the participants involved. Every human participant provided their consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"171"}}